3 March 2020

Scancell Holdings plc
("Scancell" or the "Company")

Scancell to present at three research conferences, illustrating some of the recent progress on its platform technologies

Scancell Holdings plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, announces that its Chief Scientific Officer and Professor of Cancer Immunotherapy at the University of Nottingham, Professor Lindy Durrant, Ph.D., will be presenting at the following three conferences in March 2020:

- The Cambridge Healthcare Institute's (CHI) Immuno-Oncology Summit Europe 2020 in London (9th – 12th March 2020)
- The 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress in London (12th – 13th March 2020)
- The 5th Skin Vaccination Summit 2020 in Edinburgh (17th March 2020 – 19th March 2020)

The presentations by Professor Durrant will highlight the recent progress made across the Company's technology platforms including Moditope® and AvidiMab™.

At the CHI Summit, Professor Durrant will give a featured presentation on Tuesday 10th March entitled *'Stress induced post-translational modifications (siPTMs) as targets for cancer vaccines'* focusing on citrullination as a widely expressed, novel, stress induced post-translational modification that is a potent target for cancer vaccines such as those based on Scancell's Moditope® platform.

The focus of the MarketsandMarkets Next Gen Immunology Congress is on developments in the field of monoclonal antibodies including antibody drug conjugates, bispecific antibodies, biomarkers, T cell receptor (TCR) approaches and CART-T cell therapies. Professor Durrant will give a presentation on Thursday 12th March entitled *'AvidMabs, Fc engineering to enhance the avidity of monoclonal antibodies'* focusing on Scancell's new antibody engineering technology, AvidiMab™, and the identification of a panel of antibodies that recognise tumour-assoicated glycans.

The Skin Vaccination Summit will concentrate on the skin as an ideal target to induce potent immune responses and more efficacious vaccines. On Wednesday 18th March Professor Durrant will present *'Targeting citrullinated vimentin and enolase with cytotoxic CD4 T cells relies upon MHC-II expression by tumors, reduces myeloid suppressor cells and directly kills tumor cells'* describing the translation of its lead Moditope® vaccine, Modi-1, into a intradermal immunotherapy with clinical utility for patients with solid tumours.

The company has also previously presented data at the British Society for Immunology Congress held in Liverpool in December 2019. Members of Professor Durrant's research team presented two posters, including one on the further scientific understanding of the Moditope® platform and one on FG2811, its ultra-specific antibody with the ability to induce human stem memory T cell proliferation and differentiation, and the potential to be utilised *in vivo* for cancer immunotherapy or to provide cells for CAR-T or TCR adoptive cell therapies.

The poster presentations were as follows and are available on the Company's website, at: https://www.scancell.co.uk/scientific-papers-posters

- "Induction of post-translational modifications in tumour and their recognition by T cells" by Nottingham University and Scancell
- "An ultraspecific anti-SSEA-4 monoclonal antibody recognizes stem memory T cells" by Scancell, Nottingham University and Josep Carreras Leukaemia Research Institute

For Further Information:

Scancell Holdings plc
Dr John Chiplin, Chairman +44 (0) 20 3727 1000
Dr Cliff Holloway, CEO

Panmure Gordon (UK) Limited
(Nominated Adviser and Corporate broker)
Freddy Crossley/Emma Earl +44 (0) 20 7886 2500

FTI Consulting +44 (0) 20 3727 1000
Simon Conway/Natalie Garland-Collins

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.

ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system. They have the potential to be used as monotherapy or in combination with checkpoint inhibitors and other agents. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.

- SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.

- SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK (CRUK) for SCIB2.

Moditope® represents a completely new class of potent and selective immunotherapy agents based on stress-induced post-translational modifications (siPTM). It stimulates the production of killer CD4 T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope® alone, or in combination with other agents, has the potential to treat a wide variety of cancers.

- Modi-1 is being developed for the treatment of solid tumours including triple negative breast cancer, ovarian cancer and head and neck cancer.

AvidiMab™ is a patent protected technology platform which increases the avidity of human antibodies by promoting non-covalent Fc-Fc interactions. This modification induces the direct tumour cell killing properties of Scancell's anti-glycan monoclonal antibodies (mAbs) but has broad potential to increase the avidity or potency of any therapeutic monoclonal antibody including those being developed for autoimmune diseases, as well as cancer.

For further details, please see our website: www.scancell.co.uk